Evidence map›Paper›PMID 41656417›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

[

Xinchun Yan, Xiaoyuan Li, Guoyang Zheng, Mingwei Ma, Meixi Liu, Jingnan Wang, Yushi Zhang, Yi Ba, Xianshu Gao, Wenjia Zhu and 1 more

Abstract readComparative StudyClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinchun Yan *Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Xiaoyuan Li *Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Guoyang ZhengDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Mingwei MaDepartment of Radiation Therapy, Peking University First Hospital, Beijing, China.
Meixi LiuDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Jingnan WangDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Yushi ZhangDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Yi BaDepartment of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Xianshu GaoDepartment of Radiation Therapy, Peking University First Hospital, Beijing, China.
Wenjia ZhuDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan, Dongcheng District, Beijing, 100730, China. zhuwenjia_pumc@163.com.ORCID 0000-0002-6104-4440
Li HuoDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan, Dongcheng District, Beijing, 100730, China. huoli@pumch.cn.

Funding

National Natural Science Foundation of China 82202218
6 · The paper itself

Abstract

purposeThis study aimed to compare the diagnostic performance of CAIX-targeted [68Ga]Ga-NY104 PET/CT versus standard [18F]FDG PET/CT in metastatic clear cell renal cell carcinoma (ccRCC).

methodsIn this prospective single-center trial (NYCRM), 45 patients with histologically confirmed metastatic ccRCC underwent paired [68Ga]Ga-NY104 and [18F]FDG PET/CT scans within 7 days. Lesions were evaluated using a standardized composite reference (histopathology, imaging, and follow-up). Primary endpoints were lesion- and region-level sensitivity/specificity; secondary endpoints included SUVmax, tumor-to-background ratios (TBR), and clinical management impact.

resultsAmong 682 analyzed lesions, [68Ga]Ga-NY104 demonstrated superior sensitivity (94.4% vs. 78.2%, P < 0.001) and specificity (98.9% vs. 5.5%, P < 0.001) compared to [18F]FDG. Region-level analysis confirmed these findings (sensitivity: 97.0% vs. 82.2%; specificity: 97.5% vs. 10.0%). [68Ga]Ga-NY104 showed higher ccRCC lesion uptake (SUVmax: 12.4 ± 11.8 vs. 7.5 ± 10.7; TBR: 15.3 ± 14.6 vs. 4.7 ± 5.5, both P < 0.001) and lower non-ccRCC uptake (P < 0.001). Notably, [68Ga]Ga-NY104 identified 47 additional metastatic regions in 53% of patients and altered clinical management in 24% (11/45), including treatment intent or modality changes.

conclusionThis prospective head-to-head comparison between [68Ga]Ga-NY104 and [18F]FDG PET/CT in 45 patients with metastatic ccRCC shows superior sensitivity and specificity with [68Ga]Ga-NY104 PETCT than with [18F]FDG. It indicates that CAIX-targeting PET should be the PET tracer of choice over [18F]FDG in restaging ccRCC.

Indexed as

Carcinoma, Renal CellFluorodeoxyglucose F18Gallium RadioisotopesKidney NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisProspective StudiesRadiopharmaceuticalsSensitivity and SpecificityFluorodeoxyglucose F18Gallium-68Gallium RadioisotopesRadiopharmaceuticalsCarbonic anhydrase IXClear cell renal cell carcinomaFDGNY104

Identifiers

PMID41656417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.